HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

STAA

STAAR Surgical Company (NASDAQ)

Healthcare — Medical Instruments & Supplies

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

None 9 analysts
$28.36
+$0.21 (+0.75%)
Target: $29.67 (4.6%)
Sign in to add STAA to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.41B
P/E Ratio (TTM)-
Forward P/E28.72
EPS (TTM)$-0.42
Dividend Yield-
Profit Margin-7.24%
Revenue Growth119.60%
ROE-5.99%
Debt/Equity10.58
Recommendation None
Analyst Target$29.67
Analysts9
Indexes NASDAQ

Technical Indicators

RSI (14)46.8
Beta1.23
SMA 20-
SMA 40-
52-Week High$35.87
52-Week Low$15.59
50-Day Avg$28.93
200-Day Avg$24.45
Avg Volume966.3K
Volume5.7K

Performance Analysis

NEUTRAL

STAA presents a mixed picture with both positive and negative indicators.

~ Trading at 63% of its 52-week range.
~ RSI at 46.8 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
+ Strong revenue growth of 119.6% year-over-year.
- Operating at a loss with -7.2% margin.
~ Wall Street consensus is "none" from 9 analysts.
+ Average analyst target of $29.67 implies 4.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:32 UTC

Back to Screener Export Report